Gilead Science (GILD) Followers Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gilead Science (GILD) Followers

GILD 122.59

+1.2%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: GENE DAVID HART who wrote (211)	2/18/1997 11:35:00 AM
From: Skywatcher	of 961

Excellent results from Phase II/III trials with VISTIDE. Retinitis was substantially delayed in HIV patients. Lower required dosages and less frequent administrations of the drug led to much lower side effects than the other known drugs. Doctors examined about 48 patients with opthomological exams without knowing who was using the drug. Good news...hope someone can post the actual news release for us, but that is the gist of it. They are also looking at increased overseas sales of the product. chris

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next